Schizophrenia: all 3,539 studies

Page 25 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.

• Shared Decision Making for Patients With First-admission SchizophreniaCompletedNCT01869660Phase 2/3
• The Effect of Paliperidone Palmitate in SchizophreniaCompletedNCT01860781Phase 4
• Geriatric Psychiatry and PharmacovigilanceStatus unknownNCT01858857
• Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With SchizophreniaCompletedNCT01852331Phase 2
• Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy SubjectsTerminatedNCT01851603Phase 1
• Effects of Varenicline on Smoking Lapse in Smokers With and Without SchizophreniaCompletedNCT01850953Phase 4
• Tobacco Craving and Triggers in Persons With SchizophreniaCompletedNCT01846065
• Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)TerminatedNCT01834638Phase 2
• Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia PatientsStatus unknownNCT01832285Not applicable
• Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective DisordersStatus unknownNCT01831986Not applicable
• Lifestyle Intervention for Diabetes and Weight Management in PsychosisCompletedNCT01828931Not applicable
• Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)CompletedNCT01822418Phase 4
• A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic PatientsCompletedNCT01819818
• Enhancing Motivation in Recent Onset SchizophreniaTerminatedNCT01817387Not applicable
• Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to SchizophreniaTerminatedNCT01813955Early Phase 1
• A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable SchizophreniaCompletedNCT01812642Phase 2
• Minocycline for SchizophreniaCompletedNCT01809158Phase 4
• Exploration of the Social Cognition in Adolescents With a Dissociative Disorder or Autism SpectrumCompletedNCT01805128Not applicable
• D-Serine Treatment For Tardive DyskinesiaStatus unknownNCT01804920Not applicable
• Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in SchizophreniaCompletedNCT01801787Not applicable
• Physician Survey on Monitoring of Patients Treated With QuetiapineCompletedNCT01795326
• Effectiveness and Safety of Amisulpride in Chinese Patients With SchizophreniaCompletedNCT01795183Phase 4
• Valacyclovir Augmentation for Cognitive and Functional Remediation in SchizophreniaCompletedNCT01794897Phase 4
• Treatment of Antipsychotic-associated Obesity With a GLP-1 AnalogueCompletedNCT01794429Phase 3
• EMR Data to Assess Monitoring of Patients Treated With QuetiapineCompletedNCT01793324
• Coaching Intervention for Patients With Early PsychosisStatus unknownNCT01792856Not applicable
• Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose StrengthsCompletedNCT01788774Phase 1
• A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy VolunteersCompletedNCT01788436Early Phase 1
• Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.CompletedNCT01786369
• Neuroplasticity-oriented Cognitive Intervention in Early Onset and First Admission SchizophreniaCompletedNCT01781364Not applicable
• Cerebral Reorganization in SchizophreniaCompletedNCT01781000Not applicable
• Effectiveness of Adherence Therapy for SchizophreniaCompletedNCT01780116Phase 1/2
• Enhancing Synaptic Plasticity and Cognition in SchizophreniaCompletedNCT01776112Not applicable
• Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane ImplantCompletedNCT01774435Phase 1
• Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset SchizophreniaCompletedNCT01773239Not applicable
• Adherence and Quality of Life in People With Schizophrenia and Schizoaffective DisorderStatus unknownNCT01769014
• Contrasting Group Therapy Methods for PsychosisTerminatedNCT01764568Not applicable
• Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic SchizophreniaCompletedNCT01761383Not applicable
• Vitamin D for SchizophreniaCompletedNCT01759485Not applicable
• Antipsychotic Discontinuation in High-risk SubjectsWithdrawnNCT01758887
• Correlation Between Clinical Deterioration in Schizophrenic Patients and Hair Cortisol LevelsCompletedNCT01754532
• My Coach Connect: An Automated Telephone-based Reporting System for Patients With Mental IllnessCompletedNCT01749124Not applicable
• A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy VolunteersCompletedNCT01749098Phase 1
• The Management of Schizophrenia in Clinical Practice (MOSAIC)CompletedNCT01746134
• tDCS to Enhance Cognitive Training in SchizophreniaCompletedNCT01733602Phase 1/2
• A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia PatientsCompletedNCT01730768Phase 2
• Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)CompletedNCT01729650Not applicable
• Measuring the Effect of Remote Monitoring of Treatment Adherence on the Risk of Re-admission of Ambulatory Schizophrenic PatientsStatus unknownNCT01729572Not applicable
• Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in SchizophreniaWithdrawnNCT01725334Phase 1
• A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in EthiopiaCompletedNCT01724476Phase 4
• Improving Work Outcome for People With Severe Mental IllnessCompletedNCT01722344Not applicable
• Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyCompletedNCT01716975Phase 3
• An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With SchizophreniaCompletedNCT01716858Phase 2
• A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyCompletedNCT01714713Phase 3
• Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyCompletedNCT01714661Phase 3
• Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic SyndromeCompletedNCT01714011Phase 4
• Daily Intranasal Oxytocin for Childhood-Onset SchizophreniaTerminatedNCT01712646Phase 1/2
• Cognitive Behavioral Therapy for Paranoia in SchizophreniaCompletedNCT01704833Not applicable
• Cognitive Remediation Therapy (CRT) in Adolescents With EOSCompletedNCT01701609Not applicable
• Oxytocin as Adjunctive Therapy for SchizophreniaCompletedNCT01699997Phase 2
• Switching From Consta® to Sustenna® in Patients With SchizophreniaCompletedNCT01698216
• Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational StudyCompletedNCT01689389
• Apathy in SchizophreniaCompletedNCT01689181
• Cross-Sectional Iloperidone IVGTTCompletedNCT01686815
• A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral AntipsychoticsCompletedNCT01685931Phase 4
• Understanding How Cognitive Remediation WorksCompletedNCT01683539Not applicable
• A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone PalmitateCompletedNCT01682161Phase 4
• A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaCompletedNCT01678755Phase 2
• Clinical Symptoms of Schizophrenia and Physical ExerciseCompletedNCT01674543Not applicable
• Clinical Benefits of Seroquel XR in Anxiety DisorderStatus unknownNCT01672554Phase 3
• A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With SchizophreniaTerminatedNCT01670071Phase 4
• Mindfulness-based Illness Management Program for SchizophreniaCompletedNCT01667601Not applicable
• Internalized Stigma in Patients With Bipolar Disorder or SchizophreniaStatus unknownNCT01664884
• Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic PatientsCompletedNCT01663077Phase 4
• Validation of Receptor Occupancy SimulationCompletedNCT01660880
• A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in SchizophreniaCompletedNCT01655680Phase 2
• Schizophrenia ImagingStatus unknownNCT01655472Not applicable
• Group Intervention for Improving Stigma Coping and Empowerment of People With Mental Illness (STEM)CompletedNCT01655368Not applicable
• The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking ClozapineTerminatedNCT01654640Phase 4
• Antipsychotic Augmentation With L-DopaCompletedNCT01636037Phase 2
• Acute Effects of Exercise in Smokers With SchizophreniaCompletedNCT01635075Phase 2
• An Non-Interventional Study of Patients With Persistent Symptoms of SchizophreniaCompletedNCT01634542
• Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine TabletsCompletedNCT01634373Phase 1
• Auditory Brainstem Response as a Diagnostic Tool in Schizophrenia and Bipolar DisorderCompletedNCT01629355
• Social Cognition in Longstanding PsychosisTerminatedNCT01624831
• Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in SchizophreniaWithdrawnNCT01623726Phase 2
• Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat SchizophreniaCompletedNCT01623713Phase 2
• Art Therapy in Acute SchizophreniaCompletedNCT01622166Not applicable
• Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of PsychosisCompletedNCT01619319Not applicable
• Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)CompletedNCT01617200Phase 3
• A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of SchizophreniaTerminatedNCT01615185Phase 4
• Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in PsychiatryCompletedNCT01611337Not applicable
• Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to MonotherapyCompletedNCT01609153Phase 4
• Effects of Transcranial Direct Current Stimulation in Individuals With SchizophreniaCompletedNCT01607840Not applicable
• Specific Cognitive Remediation for SchizophreniaCompletedNCT01607424Not applicable
• Transcranial Direct Current Stimulation (tDCS) and Cognitive ProcessingCompletedNCT01602263
• Randomized Double Blind Placebo Control Study in Patients with SchizophreniaCompletedNCT01602029Phase 2
• Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective PatientsStatus unknownNCT01598623Phase 2
• Computer Assisted Cognitive Remediation Program in SchizophreniaCompletedNCT01598220Not applicable
• Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive DisorderCompletedNCT01596608Not applicable

← Schizophrenia overview